We are focused on bringing psychedelic medicine to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing.
Core One Labs Investor Webcast - Friday January 21, 2022
Psychedelic inspired delivery methods
Patent pending delivery methods, used for safe, accurate dosing of natural occurring compounds
Advancing Psychedelics Research and Development
Developing a pipeline of patent pending, cost effective cGMP psychedelic compounds for the furtherance of mental health and neurological disorders research
Facilitating Patient Access to legal psychedelic treatments
Core One Labs is a leading life sciences company
A new type of pharma company focused on overall patient health
Mental health and addiction is a growing problem for people around the world and we are working on a solution.
We are focused on advancing the use of psychedelic medicines through novel delivery systems, specialized assisted psychotherapy, and API grade psilocybin manufacturing.
24 January, 2023 Core One Labs’ Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
13 January, 2023Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and other Drug Developers